Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on October 11, 2007
Japanese Journal of Clinical Oncology 2007 37(11):820-828; doi:10.1093/jjco/hym114
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
37/11/820    most recent
hym114v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sugiura, H.
Right arrow Articles by Yamashita, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugiura, H.
Right arrow Articles by Yamashita, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Expression of Estrogen Receptor β Wild-type and its Variant ERβcx/β2 is Correlated with Better Prognosis in Breast Cancer

Hiroshi Sugiura1, Tatsuya Toyama1, Yasuo Hara1, Zhenhuan Zhang1, Shunzo Kobayashi1, Yoshitaka Fujii1, Hirotaka Iwase2 and Hiroko Yamashita1,

1 Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya
2 Breast and Endocrine Surgery, Kumamoto University, Kumamoto, Japan

For all reprints and correspondence: Hiroko Yamashita, Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-ku, Nagoya 467-8601, Japan. E-mail: hirokoy{at}med.nagoya-cu.ac.jp

Received May 7, 2007; accepted July 23, 2007

Background: The clinical value of estrogen receptor (ER) β and its variants has been investigated. However, reported results have frequently been discordant.

Methods: We investigated mRNA and protein expression of ERβ wild type (ERβ1) and its variant, ERβcx/β2, by quantitative real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry in 150 breast cancer tissues, and analyzed association between their expression and clinicopathological factors and prognosis.

Results: ERβ1 mRNA expression was significantly correlated with progesterone receptor expression and low histological grade. ERβ1 protein expression was significantly correlated with small tumor size, negative lymph node status and low histological grade. ERβcx/β2 protein expression was significantly correlated with ER{alpha} expression and low histological grade. Patients with high expression of ERβ1 or ERβcx/β2 had a significantly better disease-free and overall survival than those with low expression. In multivariate analysis, ERβcx/β2 mRNA expression was identified as a prognostic factor in disease-free and overall survival.

Conclusion: Our results indicate that ERβcx/β2 mRNA expression is an independent prognostic factor in breast cancer. ERβ expression status, both wild-type and the variant cx/β2, might represent significant predictors of breast cancer prognosis.

Key Words: breast cancer • estrogen receptor β • prognosis

Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; PgR, progesterone receptor; RT-PCR, reverse transcriptase-polymerase chain reaction.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.